59 results about "Autologous platelet" patented technology

Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing composition can thicken the wall of a heart, or act to prevent further thinning and thereby provide resistance against further remodeling. A number of compositions are disclosed, including multi-component substances such as autologous platelet gel, and other substances. The compositions disclosed can contain additives to augment / enhance the desired effects of the injection.

Methods and kits are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The kit includes components for the preparation of platelet-rich plasma from the patient's blood and components for administration to an area in need of vascularization. The methods and kits are useful for the treatment of tendinosis, and in particular, lateral epicondylitis and plantar fasciitis.

Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing composition can thicken the wall of a heart, or act to prevent further thinning and thereby provide resistance against further remodeling. A number of compositions are disclosed, including multi-component substances such as autologous platelet gel, and other substances. The compositions disclosed can contain additives to augment / enhance the desired effects of the injection.

Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing composition can thicken the wall of a heart, or act to prevent further thinning and thereby provide resistance against further remodeling. A number of compositions are disclosed, including multi-component substances such as autologous platelet gel, and other substances. The compositions disclosed can contain additives to augment / enhance the desired effects of the injection.

The invention discloses a mesenchymal stem cell self-preserving liquid which is prepared from the following raw materials according to volume ratios: 1-6% of self platelet lysate, 95-97% of solution medium and 0-1% of vitamin C injection, wherein the solution medium is a mixed sugar electrolyte injection or physiological saline injection. The mesenchymal stem cell self-preserving liquid has the advantages that: growth factors contained in the mesenchymal stem cell self-preserving liquid can maintain the activity state of cells, the vitamin C can maintain the activity of various peroxidases, at the same time, the mixed sugar electrolyte injection is especially suitable for cell preservation, and osmotic pressure is also favorable for nutrient absorption of the cells so as to carry out metabolism; the activity of the mesenchymal stem cells which are preserved in the mesenchymal stem cell self-preserving liquid within 8 hours is still larger than 90%, the cell activity change is not larger than 7%, and the activity of the mesenchymal stem cells which are preserved in the mesenchymal stem cell self-preserving liquid within 12 hours is still maintained at 85%; and by using the mesenchymal stem cell self-preserving liquid, the requirements for human intravenous back-transfusion safety can be met, and the cell preserving problem of long-time transport is solved, thus more patients have opportunity to undergo mesenchymal stem cell treatment.

Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.

The present invention relates to the production of platelet gels formed into beneficial geometric shapes. Specifically the present invention provides a simpler way to introduce platelet gel for specific uses, such as into the cavity of a gum left after a tooth extraction. Molds of predetermined shapes are provided for forming the desired shape.

Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed.

The invention discloses a preparation method of an autologous platelet-factor-rich plasma (PFRP) preparation. The preparation method is characterized by comprising the steps of: A, preparation of autologous PFRP, to be specific, collecting autologous whole blood, and preparing the autologous PFRP in a centrifuging and freeze-thawing manner; and B, preparation of the PFRP preparation, to be specific, mixing the obtained PFRP with a biological scaffold / autologous somatic cells according to a volume ratio of (3:1)-(1:1) to obtain the PFRP preparation. By means of specially processing the autologous whole blood to obtain the autologous PFRP, pollution risks caused by adding an activating agent are reduced, and the immune risks of a membrane antigen during heterogenous usage are avoided. The autologous PFRP preparation prepared according to the method not only has a good effect of repairing damaged tissues such as meniscus, but also has very good anti-wrinkle, filling and lifting effects.

Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.

The invention belongs to the technical field of cosmetic mini-plastic surgery and specifically discloses a method for preparing autologous beautifying micro-needle preparation and application thereof. The preparation of the micro-needle preparation comprises the following steps: separating autologous platelet-rich plasma and peripheral blood mononuclear cells; culturing by using an autologous activated cell factor solution and a cell culture medium; replacing a fresh autologous activated cell factor solution and a cell culture medium the next day; collecting circulating fibrocytes, endothelial progenitor cells and immune cells on the fifth day, resuspending by using the autologous platelet-rich plasma and autologous plasma, thereby obtaining the autologous beautifying micro-needle preparation. Compared with the prior art, the method disclosed by the invention has the advantages that a composition of the circulating fibrocytes, endothelial progenitor cells, immune cells and platelet-rich plasma is used for cosmetic preparations, the circulating fibrocytes are capable of reconstructing skin tissues, secreting collagens and eliminating wrinkles; the endothelial progenitor cells can achieve the effects of local skin microcirculation and improving the skin nutrition state; the immune cells can achieve the effects of swallowing and taking away metabolic products; and the combination of the endothelial progenitor cells and the immune cells can achieve the effects of repairing spotted dull skin.

A process is disclosed for preparing an autologous platelet gel and membranes thereof comprising mixing a platelet concentrate with a calcium salt and batroxobin. This process encompassing the use of batroxobin as the gel activator allows to overcome the prior art processes drawbacks connected with the use for the same purpose of human of bovine thrombin. A kit is also described for carrying out this process.

The invention discloses an adipose tissue preserving fluid in vitro and preparation method thereof. The adipose tissue preserving fluid in vitro is prepared by following components as per following parts by weight: 0.5-1.5 parts of autologous platelet lysate, 0-5 parts of sodium hyaluronate, 1-5 parts of human albumin, 0-1 part of Vitamin C, 0.1-0.3 parts of trehalose, 10-20 parts of thermo-sensitive hydrogel, 0.3-1.5 parts of antibacterial agents and 80-90 parts of phosphate buffer; the preparation method comprises mixing of above components as corresponding parts by weight under aseptic conditions to prepare the adipose tissue preserving fluid in vitro; the adipose tissue preserving fluid in vitro prepared by the method allows the adipose tissue to be evenly dispersed into the preservingfluid and allows the adipose tissue to fully contact with the preserving fluid, which is beneficial to long-term storage of the adipose tissue.

The described invention provides soft tissue grafts, hard tissue grafts, and composite soft / hard tissue grafts and methods of producing such grafts. The grafts comprise a three-dimensional carrier matrix, a growth factor composition comprising an autologous platelet-rich fibrin and a cell culture composition comprising a culture medium, a population of cells suspended in the culture medium, and cells impregnated on or in a surface of osteoconductive particles.

The invention provides a stem cell injection for treating osteoarthritis cartilage defect and preparation and application thereof. The injection comprises fifth-generation umbilical cord mesenchymal stem cells and a liquid solvent, wherein the fifth generation umbilical cord mesenchymal stem cells are suspended in the liquid solvent, and the concentration is (2.0-3.0)x10<7> cells / 4.5-5.0ml of the liquid solvent. The liquid solvent is normal saline, or autologous platelet-rich plasma, or a mixed solution of normal saline and human albumin, or a mixed solution of normal saline and autologous platelet-rich plasma. The human albumin accounts for 5-8% in volume by percentage. The normal saline accounts for 10% or below in volume by percentage. The injection is administered by intravenous injection or bone joint cavity local injection or the combination of the two, the cell injection amount of the intravenous injection is (1.0-1.5)x10<8> cells / one time, and the cell injection amount of the bone joint cavity injection is (2.0-3.0)x10<7> cells / one time / one knee. The effect of the stem cell injection for treating the integrity degree of osteoarthritis cartilage is obviously superior to that of a traditional hyaluronic acid (HA) method.

The invention discloses a stem cell preparation for treating primary liver cancer and a preparation method thereof. The preparation contains (60-100)*10<6> pieces / ml of mesenchymal stem cells, 20ng / ml of HGF and 10ng / ml of FGF-4, and takes autologous platelet-rich plasma lysate as a solvent. The preparation method comprises the following steps of: (1) collecting an umbilical cord, and carrying out primary culture to obtain cells; (2) detecting by using a flow cytometry, wherein such cells express CD29, CD73, CD90 and CD105; (3) collecting cells, namely dissolving (60-100)*10<6> mesenchymal stem cells of the human umbilical cord in 1 ml of autologous platelet-rich plasma lysate, and adding 20ng of HGF and 10ng of FGF-4 to be prepared into 1 ml of a stem cell preparation. According to the stem cell preparation disclosed by the invention, the source of raw materials is rich, the raw materials are easy to obtain, the umbilical cord mesenchymal stem cells are weakly immunogenic, and platelet-rich plasma is taken from the patients, so no immunogenicity exists.

Methods for ameliorating stent graft migration and endoleak using treatment site-specific cell growth promoting compositions in combination with stent grafts are disclosed. Also disclosed are application of cell growth promoting compositions such as, but not limited to, autologous platelet gel compositions directly to treatment sites before, during or after stent graft implantation. Additional embodiments include medical devices having autologous platelet gel coatings and / or autologous platelet gel delivery devices useful for treating aneurysms.

The invention relates to a kit for integrally preparing autologous platelet-rich plasma. The kit comprises a plasma storage pipe, a connecting pipe and an erythrocyte storage pipe seal cover, wherein the connecting pipe sequentially comprises a PRP storage pipe, a locking pipe and an erythrocyte storage pipe which are integrated; the plasma storage pipe is in threaded connection with the PRP storage pipe; the erythrocyte storage pipe is in threaded connection with the erythrocyte storage pipe seal cover; a plasma extraction draining pipe and a PRP extraction draining pipe are arranged in the plasma storage pipe, and the length of the PRP extraction draining pipe is more than that of the plasma extraction draining pipe; a plasma extraction opening and a PRP extraction opening are formed in the top of the plasma storage pipe, the plasma extraction opening is communicated with the plasma extraction draining pipe, and the PRP extraction opening is communicated with the PRP extraction draining pipe; an erythrocyte locking plug is arranged in the locking pipe; the opening formed in the bottom of the plasma storage pipe is matched with the erythrocyte locking plug. The kit has the advantage of completing the whole extraction process in an integral device, is simple, quick and efficient, and is hardly polluted.

A method and kit to produce activated autologous platelet rich and platelet poor plasma (AAPRPP) and methods of use to treat pain. The method to produce AAPRPP generally comprising (1) obtaining whole blood from patient; (2) centrifuging whole blood in a collection tube; (3) extracting platelet rich and platelet poor plasma mixture from collection tube; and (4) transferring platelet rich and platelet poor plasma mixture to an activation tube containing at least one platelet aggregator and at least one platelet activator to obtain a resulting platelet concentration. The method to treat pain generally comprising producing AAPRPP and extracting contents of activation tube into a standard syringe then injecting AAPRPP at or near the nerve group responsible for the affected anatomical area.

Provided is a blood separating vessel for extracting autologous platelets, and an apparatus for extracting autologous platelets. The blood separating vessel for extracting autologous platelets comprises: a main body defining an internal space divided into an upper fluid chamber and a lower fluid chamber; an upper cover disposed to seal an upper portion of the upper fluid chamber; a lower cover disposed to seal a lower portion of the lower fluid chamber, the lower cover being coupled such that an outer peripheral surface of the lower cover is elevatable in a state of being in close contact along an inner peripheral surface of the lower fluid chamber by an external force applied upward; and a fluid collection part dividing the internal space into the upper fluid chamber and the lower fluid chamber and including a fluid passage protruding upward to communicate the upper fluid chamber with the lower fluid chamber.

The present invention relates to an injection for repairing skin injury of human body. It is made up by using auto-platelet-enriched plasma, blood coagulation factor (thrombase) and calcium ion through a certain preparation process. Said invention also provides the concrete steps of its preparation process and its application method.

The invention discloses a method for preparing an autologous triple skin fibroblast preparation. The autologous triple skin fibroblast preparation comprises platelet-rich plasma, autologous collagen concentrate and fibroblasts, wherein the ratio of platelet-rich plasma to the autologous collagen concentrate is 1 to 4; and the concentration of autologous fibroblasts is (1.0-2.0)*10<7> / mL. The preparation method comprises the following steps: separating and culturing human skin fibroblast; preparing the high-concentration autologous collagen solution; preparing autologous platelet-rich plasma; and preparing an autologous triple skin fibroblast injection preparation. Active ingredients of the preparation disclosed by the invention are all from a customer, and are cultured in an autologous serum medium during the cultivation of fibroblasts, so that the preparation is truly safe, effective and individualized. The preparation can be used for skin wrinkle removal, scar repairing, regeneration and other effects, so as to solve a problem of skin aging.

The invention relates to an integrated autologous platelet rich gel preparation set, which includes a plasma storage pipe, a connecting pipe and a red blood cell storage pipe seal cover. The connecting pipe is composed of an integrated PRP storage pipe, locking pipe and red blood cell storage pipe in order, the plasma storage pipe and the PRP storage pipe are in threaded connection, and the red blood cell storage pipe and the red blood cell storage pipe seal cover are in threaded connection. The plasma storage pipe is internally provided with a plasma extraction guide pipe and a PRP extraction guide pipe, the length of the PRP extraction guide pipe is larger than that of the plasma extraction guide pipe, the top of the plasma storage pipe is equipped with a plasma extraction port and a PRP extraction port, the plasma extraction port and the plasma extraction guide pipe are communicated, the PRP extraction port and the PRP extraction guide pipe are communicated. The locking pipe is internally provided a red cell lock plug, and the port at the bottom of the plasma storage pipe matches with the red cell lock plug. The set provided by the invention has the advantages of ability to complete the whole extraction process within an integrated device, simplicity, speediness and high efficiency, and difficult pollution.

Described herein are systems and methods for soft tissue reconstruction and augmentation using a platelet-rich fibrin matrix. In one embodiment the system of the present invention includes a blood collection apparatus capable of drawing blood from a patient, a matrix preparation container configured to hold a patient's blood while the blood is separated and coagulated to form a platelet-rich fibrin matrix therein, and a matrix delivery device configured to receive the matrix preparation container therein and compress and force the platelet-rich fibrin matrix out of the matrix preparation container and into the patient. In another embodiment the invention described herein is a method in which blood is drawn from a patient and separated and coagulated to form a platelet-rich fibrin matrix. The platelet-rich fibrin matrix is implanted into a patient at the site of a tissue defect or where tissue augmentation is desired.

The invention discloses mixed freeze-dried powders of platelet-rich plasma combined with excreted factors of human mesenchymal stem cells and a preparation method thereof. The method comprises steps:preparing platelet-rich plasma; culturing excreted factor of mesenchymal stem cells; performing freeze-drying on the platelet-rich plasma and the excreted factor of mesenchymal stem cells, and mixingthe platelet-rich plasma and the excreted factor of mesenchymal stem cells, wherein weight percentage of self platelet-rich plasma contained in the mixed freeze-dried powders is larger than that of the excreted factor of mesenchymal stem cells. Autoblood and human cells are used as materials, to improve human absorption benefit and security, and a used nutrient solution is human platelet serum butnot animal fetal calf serum, to reduce protein variation. A freeze-drying technology is used to overcome a deterioration problem caused by heat sensitivity and aging, and meanwhile ratio of the mixedfreeze-dried powders can be customized, so as to be used in different environments later.

The invention provides a single surgical procedure by using autologous platelet-rich fibrin (PRF) and cartilage fragments to solve problems of contamination during incubation of chondrocytes and transplant rejection in vivo, which has the benefit of a more efficient and shorter recovery time. The invention also provides a device for easily and rapidly cutting cartilage to cartilage fragments so as to reduce contamination of the implant and infection.

The invention discloses mesenchymal stem cells and exosomes of the mesenchymal stem cell and application of the mesenchymal stem cells in treating anal fistula, and further discloses a method for treating anal fistula by using an autologous-fat-derived mesenchymal stem cell mixed preparation. The stem cell preparation includes autologous-adipose-derived mesenchymal stem cells (ADSCs) and exosomes(EXO-ADSCs) of the ADSCs, autologous platelet-rich plasma (PRP) and synthetic bacteriostatic peptides (AMP). The stem cells have immunoregulatory functions, the exosomes create a micro-environment which is conducive to recovery, meanwhile, the stem cells are stimulated to release various growth factors, and wound healing is promoted. PROP gel provides support and nutrients and works synergistically with stem cells, the survival rate after stem cell transplantation is improved, and the stem cells can better play a role. The synthetic peptides are single in components and controllable and reducethe incidence of infection. The combined use greatly improves the cure rate of anal fistula.

A system for the production of a blood component composition is provided. The system includes a centrifuge having a blood reservoir for receiving and separating a blood sample into multiple components; a dispenser disposed outside of the centrifuge having a first collection chamber containing an activation agent and a second collection chamber containing one or more medicinal agents; means for removing a first portion at least one separated blood component from the centrifuge to the first container and a second portion to the second collection chamber, wherein the first collection chamber activates the first portion and stores the resulting clot and thrombin; a filter for separating the thrombin from the clot; and a nozzle for entraining and mixing the thrombin with the second portion containing the one or more medicinal components.